Ken Griffin Inmune Bio, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 29,300 shares of INMB stock, worth $129,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,300
Previous 12,400
136.29%
Holding current value
$129,506
Previous $109,000
44.04%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding INMB
# of Institutions
71Shares Held
5.92MCall Options Held
243KPut Options Held
46.4K-
Black Rock Inc. New York, NY813KShares$3.59 Million0.0% of portfolio
-
Praetorian Pr LLC Rincon, PR781KShares$3.45 Million1.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA721KShares$3.19 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$2.64 Million45.87% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$1.63 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $79.3M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...